Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Lung Cancer. 2011 Nov 1;76(1):98–105. doi: 10.1016/j.lungcan.2011.09.016

Figure 4. Comparison of 21 identified gene signatures with other lung cancer gene signatures.

Figure 4

The 21 prognostic gene signatures were compared with 11 gene signatures evaluated in the Director's Challenge Study (12) in two test sets in terms of hazard ratio (A) and concordance probability estimate [CPE] (B). The prognostic performance of the 21 gene signatures was evaluated for stage I patients by hazard ratio (C) and CPE (D), as well as for stage I patients without receiving chemotherapy in the combined test cohorts (E, F). The error bar in the charts represents 95% confidence interval of the measurement. Signatures A, C-N were from the Director's Challenge Study (12), and the details were summarized in Table S1 in our previous study (25).